Novel obesity drugs, oncology biosimilars to impact markets

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.588, 2009-01, pp. : 11-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novel anti-obesity drugs

By Proietto J.   Fam B.C.   Ainslie D.A.   Thorburn A.W.  

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 6, 2000-06 ,pp. : 1317-1326

Informa Healthcare

Access to resources Recommend Favorite

Biological Drugs and the Coming of Biosimilars

By  

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 38, Iss. 2, 2008-06 ,pp. : 137-139

John Wiley & Sons Inc

Access to resources Recommend Favorite

Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines

By Correia Marcelo LG   Haynes William G  

Expert Opinion on Emerging Drugs, Vol. 10, Iss. 3, 2005-08 ,pp. : 643-660

Informa Healthcare

Access to resources Recommend Favorite

Biosimilars

By  

Pharmazie in unserer Zeit, Vol. 41, Iss. 6, 2012-11 ,pp. : 437-437

Blackwell Publishing

Access to resources Recommend Favorite

Discontinued drugs in 2012: oncology drugs

By Williams Robert  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 12, 2013-12 ,pp. : 1627-1644

Informa Healthcare

Access to resources Recommend Favorite